High-content screening identifies inhibitors of the nuclear translocation of ATF6

Liu,Chun-Lei; Li,Xin; Gan,Lu; He,Yun-Yun; Wang,Li-Li; He,Kun-Lun

doi:10.3892/ijmm.2015.2442

High-content screening identifies inhibitors of the nuclear translocation of ATF6

Authors:
- Chun-Lei Liu
- Xin Li
- Lu Gan
- Yun-Yun He
- Li-Li Wang
- Kun-Lun He
View Affiliations

Affiliations: Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing 100853, P.R. China, Pharmacy Institute of Military Medical Sciences, Beijing 100850, P.R. China
Published online on: December 23, 2015 https://doi.org/10.3892/ijmm.2015.2442
Pages: 407-414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activating transcription factor 6 (ATF6) is a transmembrane protein that consists of a cytoplasmic domain and an endoplasmic reticulum (ER) luminal domain. As unfolded protein levels arise in the ER, the ER cytoplasmic domain of ATF6 moves to the nucleus, where it activates the transcription of a range of genes, including those involved in apoptosis. As ATF6 only becomes functional once it has moved to the nucleus, compounds that inhibit its re-localization are of therapeutic interest. The aim of the present study was to rapidly and accurately identify such compounds using a novel image‑based, high‑content screening (HCS) technique. The results from the HCS analysis were then confirmed by luciferase reporter assays, western blot analysis and the measurement of cell viability. We found that HCS identified compounds which inhibited ATF6 nuclear translocation with high specificity, as confirmed by the luciferase reporter assay and western blot analysis. Moreover, we demonstrated that 3 of the 80 identified compounds impaired ATF6-mediated induced cell death. The data from this study support the theory that HCS is a novel, high throughput method which can be used for accurate and rapid compound screening.

View Figures

View References

1	Wiseman RL and Balch WE: A new pharmacology - drugging stressed folding pathways. Trends Mol Med. 11:347–350. 2005. View Article : Google Scholar : PubMed/NCBI
2	Wiseman RL, Haynes CM and Ron D: SnapShot: the unfolded protein response. Cell. 140:590–590.e2. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hong M, Luo S, Baumeister P, Huang JM, Gogia RK, Li M and Lee AS: Underglycosylation of ATF6 as a novel sensing mechanism for activation of the unfolded protein response. J Biol Chem. 279:11354–11363. 2004. View Article : Google Scholar
4	Zhao L and Ackerman SL: Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol. 18:444–452. 2006. View Article : Google Scholar : PubMed/NCBI
5	Boot-Handford RP and Briggs MD: The unfolded protein response and its relevance to connective tissue diseases. Cell Tissue Res. 339:197–211. 2010. View Article : Google Scholar
6	Northington FJ, Chavez-Valdez R and Martin LJ: Neuronal cell death in neonatal hypoxia-ischemia. Ann Neurol. 69:743–758. 2011. View Article : Google Scholar : PubMed/NCBI
7	Mei J and Niu C: Alterations of Hrd1 expression in various encephalic regional neurons in 6-OHDA model of Parkinson's disease. Neurosci Lett. 474:63–68. 2010. View Article : Google Scholar : PubMed/NCBI
8	Chu WS, Das SK, Wang H, Chan JC, Deloukas P, Froguel P, Baier LJ, Jia W, McCarthy MI, Ng MC, et al: Activating transcription factor 6 (ATF6) sequence polymorphisms in type 2 diabetes and pre-diabetic traits. Diabetes. 56:856–862. 2007. View Article : Google Scholar : PubMed/NCBI
9	Vekich JA, Belmont PJ, Thuerauf DJ and Glembotski CC: Protein disulfide isomerase-associated 6 is an ATF6-inducible ER stress response protein that protects cardiac myocytes from ischemia/reperfusion-mediated cell death. J Mol Cell Cardiol. 53:259–267. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hotamisligil GS: Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 140:900–917. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW, Park SW and Lee WY: Exendin-4 attenuates endoplasmic reticulum stress through a SIRT1-dependent mechanism. Cell Stress Chaperones. 19:649–656. 2014. View Article : Google Scholar : PubMed/NCBI
12	Tsukumo Y, Tomida A, Kitahara O, Nakamura Y, Asada S, Mori K and Tsuruo T: Nucleobindin 1 controls the unfolded protein response by inhibiting ATF6 activation. J Biol Chem. 282:29264–29272. 2007. View Article : Google Scholar : PubMed/NCBI
13	Citron M, Diehl TS, Capell A, Haass C, Teplow DB and Selkoe DJ: Inhibition of amyloid beta-protein production in neural cells by the serine protease inhibitor AEBSF. Neuron. 17:171–179. 1996. View Article : Google Scholar : PubMed/NCBI
14	Damiano F, Tocci R, Gnoni GV and Siculella L: Expression of citrate carrier gene is activated by ER stress effectors XBP1 and ATF6α, binding to an UPRE in its promoter. Biochim Biophys Acta. 1849:23–31. 2015. View Article : Google Scholar
15	Cox DJ, Strudwick N, Ali AA, Paton AW, Paton JC and Schröder M: Measuring signaling by the unfolded protein response. Methods Enzymol. 491:261–292. 2011. View Article : Google Scholar : PubMed/NCBI
16	Bouck DC, Shu P, Cui J, Shelat A and Chen T: A high-content screen identifies inhibitors of nuclear export of forkhead transcription factors. J Biomol Screen. 16:394–404. 2011. View Article : Google Scholar : PubMed/NCBI
17	Liu J, He KL, Li X, Li RJ, Liu CL, Zhong W and Li S: SAR, cardiac myocytes protection activity and 3D-QSAR studies of salubrinal and its potent derivatives. Curr Med Chem. 19:6072–6079. 2012. View Article : Google Scholar : PubMed/NCBI
18	Toko H, Takahashi H, Kayama Y, Okada S, Minamino T, Terasaki F, Kitaura Y and Komuro I: ATF6 is important under both pathological and physiological states in the heart. J Mol Cell Cardiol. 49:113–120. 2010. View Article : Google Scholar : PubMed/NCBI
19	Adachi Y, Yamamoto K, Okada T, Yoshida H, Harada A and Mori K: ATF6 is a transcription factor specializing in the regulation of quality control proteins in the endoplasmic reticulum. Cell Struct Funct. 33:75–89. 2008. View Article : Google Scholar : PubMed/NCBI
20	Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D and Yuan J: A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science. 307:935–939. 2005. View Article : Google Scholar : PubMed/NCBI
21	Boyd JD, Lee-Armandt JP, Feiler MS, Zaarur N, Liu M, Kraemer B, Concannon JB, Ebata A, Wolozin B and Glicksman MA: A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J Biomol Screen. 19:44–56. 2014. View Article : Google Scholar :
22	Mori T, Saito F, Yoshino T, Takeyama H and Matsunaga T: Reporter gene assay against lipophilic chemicals based on site-specific genomic recombination of a nuclear receptor gene, its response element, and a luciferase reporter gene within a stable HeLa cell line. Biotechnol Bioeng. 99:1453–1461. 2008. View Article : Google Scholar
23	Gasparetto M, Gentry T, Sebti S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J and Smith C: Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. J Immunol Methods. 292:59–71. 2004. View Article : Google Scholar : PubMed/NCBI
24	Starkuviene V and Pepperkok R: The potential of high-content high-throughput microscopy in drug discovery. Br J Pharmacol. 152:62–71. 2007. View Article : Google Scholar : PubMed/NCBI
25	Feng Y, Mitchison TJ, Bender A, Young DW and Tallarico JA: Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov. 8:567–578. 2009. View Article : Google Scholar : PubMed/NCBI
26	Giuliano KA, Haskins JR and Taylor DL: Advances in high content screening for drug discovery. Assay Drug Dev Technol. 1:565–577. 2003. View Article : Google Scholar
27	Liu CL, Li X, Hu GL, Li RJ, He YY, Zhong W, Li S, He KL and Wang LL: Salubrinal protects against tunicamycin and hypoxia induced cardiomyocyte apoptosis via the PERK-eIF2α signaling pathway. J Geriatr Cardiol. 9:258–268. 2012.PubMed/NCBI